DE69830806D1 - Integrinrezeptor antagonisten - Google Patents

Integrinrezeptor antagonisten

Info

Publication number
DE69830806D1
DE69830806D1 DE69830806T DE69830806T DE69830806D1 DE 69830806 D1 DE69830806 D1 DE 69830806D1 DE 69830806 T DE69830806 T DE 69830806T DE 69830806 T DE69830806 T DE 69830806T DE 69830806 D1 DE69830806 D1 DE 69830806D1
Authority
DE
Germany
Prior art keywords
beta
alpha
receptor antagonists
integrin receptor
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69830806T
Other languages
English (en)
Other versions
DE69830806T2 (de
Inventor
E Duggan
J Perkins
S Meissner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9807384.4A external-priority patent/GB9807384D0/en
Priority claimed from GBGB9815803.3A external-priority patent/GB9815803D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of DE69830806D1 publication Critical patent/DE69830806D1/de
Application granted granted Critical
Publication of DE69830806T2 publication Critical patent/DE69830806T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
DE69830806T 1997-12-17 1998-12-14 Integrinrezeptor antagonisten Expired - Fee Related DE69830806T2 (de)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US6990997P 1997-12-17 1997-12-17
US69909P 1997-12-17
GBGB9807384.4A GB9807384D0 (en) 1998-04-06 1998-04-06 Vitronectin receptor antagonists
GB9807384 1998-04-06
US8325098P 1998-04-27 1998-04-27
US83250P 1998-04-27
US9263098P 1998-07-13 1998-07-13
US92630P 1998-07-13
GB9815803 1998-07-21
GBGB9815803.3A GB9815803D0 (en) 1998-07-21 1998-07-21 Vitronectin receptor antagonists
PCT/US1998/026485 WO1999030713A1 (en) 1997-12-17 1998-12-14 Integrin receptor antagonists

Publications (2)

Publication Number Publication Date
DE69830806D1 true DE69830806D1 (de) 2005-08-11
DE69830806T2 DE69830806T2 (de) 2006-04-27

Family

ID=27517454

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69830806T Expired - Fee Related DE69830806T2 (de) 1997-12-17 1998-12-14 Integrinrezeptor antagonisten

Country Status (8)

Country Link
EP (1) EP1044001B1 (de)
JP (1) JP2002508326A (de)
AT (1) ATE299023T1 (de)
AU (1) AU738452B2 (de)
CA (1) CA2315232A1 (de)
DE (1) DE69830806T2 (de)
ES (1) ES2243015T3 (de)
WO (1) WO1999030713A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1100506A4 (de) * 1998-07-29 2002-06-26 Merck & Co Inc Integrin rezeptor antagonisten
AU748621B2 (en) * 1998-08-13 2002-06-06 Merck & Co., Inc. Integrin receptor antagonists
CA2360305A1 (en) 1999-02-09 2000-08-17 Bristol-Myers Squibb Company Lactam inhibitors of fxa and method
MXPA01010232A (es) 1999-04-13 2002-03-27 Basf Ag Ligandos de receptores de integrina.
BR0011108A (pt) 1999-06-02 2002-03-19 Merck & Co Inc Composto, composição farmacêutica, e, processos de eliciar um efeito antagonizante do receptor da integrina, de tratamento ou prevenção da osteoporose, de tratamento ou prevenção de uma condição mediada por antagonismo de um receptor de integrina, de inibição da reabsorção óssea em um mamìfero em necessidade do mesmo, e de tratamento do desenvolvimento tumoral
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
JP2003510360A (ja) 1999-10-04 2003-03-18 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
US6849639B2 (en) 1999-12-14 2005-02-01 Amgen Inc. Integrin inhibitors and their methods of use
CA2397194C (en) 2000-01-20 2011-05-17 Mark E. Duggan Alpha v integrin receptor antagonists
JP2004511434A (ja) 2000-06-15 2004-04-15 ファルマシア・コーポレーション インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
US20040254211A1 (en) 2000-09-14 2004-12-16 Arison Byron H Alpha v integrin receptor antagonists
CA2436130A1 (en) 2001-01-29 2002-08-08 3-Dimensional Pharmaceuticals, Inc. Substituted indoles and their use as integrin antagonists
KR100861466B1 (ko) 2001-04-24 2008-10-02 메르크 파텐트 게엠베하 항혈관형성제 및 ＴＮＦα를 이용한 병용 요법
US6872730B2 (en) 2001-04-27 2005-03-29 3-Dimensional Pharmaceuticals, Inc. Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
BR0313534A (pt) * 2002-08-16 2005-07-12 Janssen Pharmaceutica Nv Antagonistas de integrinade ácido carboxìlico de piperidinoìla
WO2004058760A1 (en) 2002-12-20 2004-07-15 Pharmacia Corporation Thiazole compounds as integrin receptor antagonists derivatives
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
JP2009523813A (ja) 2006-01-18 2009-06-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌を治療するためにインテグリンのリガンドを使用する特異的な治療法
KR20090108713A (ko) 2007-01-18 2009-10-16 메르크 파텐트 게엠베하 인테그린 리간드를 사용하는 암치료용 특이적 요법 및 의약
NZ597339A (en) 2009-05-25 2013-10-25 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
PT3050878T (pt) 2013-09-24 2021-12-02 Fujifilm Corp Novo composto contendo azoto ou seu sal, ou seu complexo de metal
CN106572997A (zh) 2014-05-30 2017-04-19 辉瑞公司 作为选择性雄激素受体调节剂的腈衍生物
CA3054604A1 (en) 2017-02-28 2018-09-07 Morphic Therapeutic, Inc. Inhibitors of .alpha.v.beta.6 integrin
MA47692A (fr) 2017-02-28 2020-01-08 Morphic Therapeutic Inc Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
AU2019327475A1 (en) 2018-08-29 2021-03-11 Morphic Therapeutic, Inc. INHIBITING αV β6 INTEGRIN
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
CN112969687A (zh) 2018-10-30 2021-06-15 吉利德科学公司 作为α4β7整合素抑制剂的喹啉衍生物
AU2019373245C1 (en) 2018-10-30 2022-10-27 Gilead Sciences, Inc. Compounds for inhibition of alpha 4β7 integrin
JP7214882B2 (ja) 2018-10-30 2023-01-30 ギリアード サイエンシーズ， インコーポレイテッド アルファ４ベータ７インテグリン阻害剤としてのイミダゾピリジン誘導体
KR20220047323A (ko) 2019-08-14 2022-04-15 길리애드 사이언시즈, 인코포레이티드 알파 4 베타 7 인테그린의 저해용 화합물
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929618A (en) * 1988-03-25 1990-05-29 Ube Industries, Ltd. Piperdine and piperazine derivatives, and antihistaminic pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
EP1044001B1 (de) 2005-07-06
WO1999030713A1 (en) 1999-06-24
ES2243015T3 (es) 2005-11-16
JP2002508326A (ja) 2002-03-19
EP1044001A1 (de) 2000-10-18
EP1044001A4 (de) 2003-01-29
AU1912899A (en) 1999-07-05
CA2315232A1 (en) 1999-06-24
ATE299023T1 (de) 2005-07-15
AU738452B2 (en) 2001-09-20
DE69830806T2 (de) 2006-04-27

Similar Documents

Publication Publication Date Title
ATE294163T1 (de) Integrin-rezeptor-antagonisten
DK1040111T3 (da) Integrinreceptorantagonister
ATE299023T1 (de) Integrinrezeptor antagonisten
DE69720771T2 (de) Integrin antagonist
CA2277273A1 (en) Integrin antagonists
ES2185009T3 (es) Antagonistas de alfa y beta 3'.
DE60035779D1 (de) Alpha v integrin-rezeptor antagonisten
YU38200A (sh) Antagonisti integrinskog receptora
YU38300A (sh) Antagonisti integrinskog receptora
ECSP992897A (es) Antagonistas del receptor de integrina

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee